

RESEARCH ARTICLE | VOLUME 144, 109210, JULY 2023

Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy

[Silvia Kochen](#)¹ • [Manuela Villanueva](#)¹ • [Liliana Bayarres](#)¹ • [Anilu Daza-Restrepo](#) •

[Silvia Gonzalez Martinez](#) • [Silvia Oddo](#) ¹  • [Show footnotes](#)

Published: May 15, 2023 • DOI: <https://doi.org/10.1016/j.yebeh.2023.109210> •



Highlights

Abstract

Keywords

References

Article info

Related Articles

Highlights

- Prospective observational open study of treatment with cannabidiol for 6 months.
- Efficacy: 86% responders, 11% non-responders, and 2% worsening.
- Dose: The responding patients ended with a mean of 329 mg/day.
- Adverse events: 34% of patients reported mild adverse events and no patient reported severe adverse effects.
- Most patients have a significant improvement in their quality of